Brief: Kazia Therapeutics Enters Collaboration With Australian And NZ Children's Haematology/Oncology Group
06/03/2023 21:22
March 7 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* ENTERED INTO COLLABORATION WITH AUSTRALIAN AND NEW ZEALAND
CHILDREN'S HAEMATOLOGY / ONCOLOGY GROUP
* COLLABORATION FOR PHASE II CLINICAL STUDY EXAMINING
PAXALISIB IN
CHILDREN WITH ADVANCED SOLID TUMOURS, INCLUDING BRAIN TUMOURS
Source text for Eikon: ID:nASX442bpv
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsBrief: Kazia Therapeutics Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt